Obese
Conditions
Brief summary
The objectives of this clinical study are to determine the tolerance of dietary supplement Lipidrive through the evaluation of several parameters : * Various blood biological parameters * Urinary parameters * Hemodynamic indicators * Cardiac function * Anthropometric variables
Detailed description
Primary objectives of this study : Evaluate the effects of two doses of the product on: * Various blood biological parameters for tolerance (preprandial): blood glucose, insulin, HOMA-IR, glycated hemoglobin, fructosamine, total cholesterol, triglycerides, HDL-cholesterol, LDL-cholesterol, oxidized LDL, us-CRP, creatinine, ASAT, ALAT, gGT, alkaline phosphatase, bilirubin, urea. * Urinary parameters: urea, creatinine. * Hemodynamic indicators: heart rate and blood pressure. * Cardiac function: ECG. * Anthropometric variables: weight, waist, hips, waist/hip ratio, body composition using bioelectric impendence analysis. Secondary objectives of this study: Evaluate the effects of the highest dose on: \- Adiponectin, leptin, TNF-α, and the evolution kinetics of blood glucose and blood insulin levels following a standard breakfast, with or without the acute administration of the Lipidrive dietary supplement. Two questionnaires (one on eating habits over 3 days and another on physical and sports activities) will be completed at various times (cf. below). A satisfaction questionnaire will also be completed at the end of the study. A serum bank will be created (ghrelin, resistin, GIP, GLP-1, IL-6, IL-1 beta, CCK), and stools will be collected at V2 and V5 for subsequent microbiota analysis (aliquoting performed by the AME2P laboratory, which will send the samples to BIOFORTIS Nantes at the end of the trial).
Interventions
DIETARY_SUPPLEMENTLipidrive
LipiDrive, 4 to 8 capsules per day, oral administration. Dose 1: 2.6 g Lipidrive per day Dose 2: 5.2 g Lipidrive per day
Sponsors
University Hospital, Clermont-Ferrand
Université Blaise Pascal, Clermont-Ferrand
Biofortis Mérieux NutriSciences
Valbiotis
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
45 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Male * Aged 45 to 65 years (inclusive) * BMI between 30 kg/m² (inclusive) and 40 kg/m² (non-inclusive) and/or a waist/hips ratio \> 0.9 * Non-smoker or smokes maximum 10 cigarettes per day * Stable weight for at least 3 months before the start of the study * Regular physical activity for 3 months before the start of the study, subject agreeing to maintain this level of activity over the course of the study * Stable eating habits for 3 months before the start of the study, subject agreeing to maintain these eating habits over the course of the study * Willing and able to comply with the protocol, subject agreeing to give their informed written consent * Registered with a social security scheme * Subject agreeing to be registered in the national directory of volunteers participating in biomedical research Following the biological screening conducted during the inclusion visit, run-in subjects will be included at the following visit according to the following criteria: * FBC with no clinically significant anomalies according to the investigator * ASAT ≤ 1.55 μkat/L or ≤ 92 U/L * ALAT ≤ 1.7 μkat/L or ≤ 101 U/L * gGT ≤ 2.55 μkat/L or ≤ 152 U/L * 45 ≤ Creatinine ≤ 104 μmol/L (± 10%) * Total bilirubin \< 17.1 μmol/L (± 10%) * 1.7 mmol/L ≤ Urea ≤ 8.3 mmol/L (± 10%) * us-CRP ≤ 5 mg/L (± 10%).
Exclusion criteria
* Confirmed or suspected food allergy to the test product (describe) * Subject with chronic condition or specific circumstances that the investigator considers incompatible with participation in the study * Subject taking anti-diabetic treatment * Subject taking lipo-regulating (fibrates, statins, nicotinic acid) or anti-dyslipidemia drugs * Subject consuming dietary supplements (V0 could be conducted at least 1 month after completely stopping the supplements) * Subject consuming grapefruit or orange juice (enzyme inhibitor) * Subject consuming food products supplemented with phytosterols, beta glucans, konjac, and/or cinnamon (V0 could be conducted at least 3 months after completely stopping the supplements) (list to be drawn up at the time of the study) * Unstable blood pressure equal to or over 160/95 * Subject undergoing treatment that, according to the investigator, could interfere with the evaluation of the study criteria * Subject who has been on a low-calorie diet in the 3 months prior to the study and/or intends to go on a diet during the study * Subject with serious history of anorexia nervosa, bulimia or other eating disorders * Vegetarian or vegan * Extreme eating habits * Subject participating in another clinical study or in an exclusion period following a previous clinical study * Subject who has received over 4500 euros in compensation since the start of the calendar year (sum can vary according to regulations) * Subject with a linguistic or physical incapacity to provide written informed consent * Refusal to provide written consent * Subject deprived of liberty by administrative or judicial order, under trusteeship or guardianship * Subject who cannot be contacted by telephone in case of emergency
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in body composition | 12 weeks | Defined as the difference V3 (12 weeks) - V2 (baseline), using bioelectric impendence analysis |
| Changes in fasting blood levels of GGT (Gamma glutamyltransferase) | 12 weeks | Defined as the difference V3 (12 weeks) - V2 (baseline) in UI/L |
| Changes in fasting alkaline phosphatase | 12 weeks | Defined as the difference V3 (12 weeks) - V2 (baseline) in UI/L |
| Changes in fasting blood bilirubin | 12 weeks | Defined as the difference V3 (12 weeks) - V2 (baseline) in µmol/L |
| Changes in fasting blood urea | 12 weeks | Defined as the difference V3 (12 weeks) - V2 (baseline) in mg/dL |
| Changes in heart rate | 12 weeks | Defined as the difference V3 (12 weeks) - V2 (baseline) in bpm |
| Changes in SBP (systolic blood pressure) and DBP (diastolic blood pressure) | 12 weeks | Defined as the difference V3 (12 weeks) - V2 (baseline) in mmHg (mean of the two measures for each parameter at each visit) |
| Changes in cardiac function (electrocardiogram, ECG) | 12 weeks | Defined as the difference V3 (12 weeks) - V2 (baseline) |
| Changes in body weight | 12 weeks | Defined as the difference V3 (12 weeks) - V2 (baseline) in kg |
| Changes in WC (waist circumference) | 12 weeks | Defined as the difference V3 (12 weeks) - V2 (baseline) |
| Changes in HC (hip circumference) | 12 weeks | Defined as the difference V3 (12 weeks) - V2 (baseline) |
| Changes in WHR (waist to hip ratio) | 12 weeks | Defined as the difference V3 (12 weeks) - V2 (baseline) |
| Changes in us-CRP | 12 weeks | Defined as the difference V3 (12 weeks) - V2 (baseline) in mg/L |
| Changes in blood creatinine | 12 weeks | Defined as the difference V3 (12 weeks) - V2 (baseline) in mg/dL |
| Changes in fasting blood glucose | 12 weeks | Defined as the difference V3 (12 weeks) - V2 (baseline) in mmol/L |
| Changes in fasting insulinemia | 12 weeks | Defined as the difference V3 (12 weeks) - V2 (baseline)) in mUI/L |
| Changes in fasting HOMA-IR | 12 weeks | Defined as the difference V3 (12 weeks) - V2 (baseline) |
| Changes in glycated hemoglobin | 12 weeks | Defined as the difference V3 (12 weeks) - V2 (baseline) in % |
| Changes in fasting fructosamin | 12 weeks | Defined as the difference V3 (12 weeks) - V2 (baseline) in µmol/L |
| Changes in fasting total cholesterol | 12 weeks | Defined as the difference V3 (12 weeks) - V2 (baseline) in mmol/L |
| Changes in fasting HDL cholesterol | 12 weeks | Defined as the difference V3 (12 weeks) - V2 (baseline) in mmol/L |
| Changes in fasting LDL cholesterol | 12 weeks | Defined as the difference V3 (12 weeks) - V2 (baseline) in mmol/L |
| Changes in fasting triglycerides | 12 weeks | Defined as the difference V3 (12 weeks) - V2 (baseline) in mmol/L |
| Changes in oxidized LDL | 12 weeks | Defined as the difference V3 (12 weeks) - V2 (baseline) in mmol/L |
| Changes in fasting blood levels of ASAT (Aspartate aminotransferase) and ALAT (Alanine aminotransferase) | 12 weeks | Defined as the difference V3 (12 weeks) - V2 (baseline) in UI/L |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in fasting blood adiponectin | 26 weeks | Defined as the difference V5 (26 weeks) - V4 (14 weeks) |
| Changes in fasting blood leptin | 26 weeks | Defined as the difference V5 (26 weeks) - V4 (14 weeks) |
| Changes in the evolution of glycemia during an oral glucid tolerance test | 26 weeks | Changes between V5 (26 weeks) and V4 (14 weeks) visits (defined as the difference V4-V3 in mmol/L) of glycemia at 15, 30, 45, 60, 90 and 120 minutes between T0 and T120 minutes following a standard breakfast and considering the following time-points: T-10, T-5, T0, T15, T30, T45, T60, T90 and T120 |
| Changes in the incremental area under the curve (glycemia response) during an oral glucid tolerance test | 26 weeks | Changes between V5 (26 weeks) and V4 (14 weeks) visits (defined as the difference V4-V3 in mmol/L) of incremental Area Under the Curve (iAUC) of glycemia between T0 and T120 minutes following a standard breakfast (iAUC0-120min) and considering the following time-points: T-10, T-5, T0, T15, T30, T45, T60, T90 and T120 |
| Changes in the glycemia Cmax during an oral glucid tolerance test | 26 weeks | Changes between V5 (26 weeks) and V4 (14 weeks) visits (defined as the difference V4-V3 in mUIl/L) of glycemia Cmax between T0 and T120 minutes following a standard breakfast and considering the following time-points: T-10, T-5, T0, T15, T30, T45, T60, T90 and T120 |
| Changes in the glycemia Δpeak during an oral glucid tolerance test | 26 weeks | Changes between V5 (26 weeks) and V4 (14 weeks) visits (defined as the difference V4-V3 in mmol/L) of Δpeak (difference from the baseline at Cmax), between T0 and T120 minutes following a standard breakfast and considering the following time-points: T-10, T-5, T0, T15, T30, T45, T60, T90 and T120 |
| Changes in the evolution of insulinemia during an oral glucid tolerance test | 26 weeks | Changes between V5 (26 weeks) and V4 (14 weeks) visits (defined as the difference V4-V3 in mUI/L) of insulinemia at 15, 30, 45, 60, 90 and 120 minutes between T0 and T120 minutes following a standard breakfast and considering the following time-points: T-10, T-5, T0, T15, T30, T45, T60, T90 and T120 |
| Changes in the incremental area under the curve (insulinemia response) during an oral glucid tolerance test | 26 weeks | Changes between V5 (26 weeks) and V4 (14 weeks) visits (defined as the difference V4-V3 in mUI/L) of incremental Area Under the Curve (iAUC) of insulinemia between T0 and T120 minutes following a standard breakfast (iAUC0-120min) and considering the following time-points: T-10, T-5, T0, T15, T30, T45, T60, T90 and T120 |
| Changes in the insulinemia Cmax during an oral glucid tolerance test | 26 weeks | Changes between V5 (26 weeks) and V4 (14 weeks) visits (defined as the difference V4-V3 in mUIl/L) of insulinemia Cmax between T0 and T120 minutes following a standard breakfast and considering the following time-points: T-10, T-5, T0, T15, T30, T45, T60, T90 and T120 |
| Changes in the insulinemia Δpeak during an oral glucid tolerance test | 26 weeks | Changes between V5 (26 weeks) and V4 (14 weeks) visits (defined as the difference V4-V3 in mUIl/L) of Δpeak (difference from the baseline at Cmax), between T0 and T120 minutes following a standard breakfast and considering the following time-points: T-10, T-5, T0, T15, T30, T45, T60, T90 and T120 |
Other
| Measure | Time frame | Description |
|---|---|---|
| Changes in stools microbiota | 26 weeks | Changes between V5 (26 weeks) and V4 (14 weeks) |
Countries
France
Outcome results
None listed